Emerging Clinical Trials Targeting the Tumor Microenvironment in Pancreatic Cancer

Why the Tumor Microenvironment Matters

Pancreatic ductal adenocarcinoma (PDAC) is surrounded by a dense desmoplastic stroma composed of collagen, hyaluronic acid, and cancer‑associated fibroblasts that raises interstitial pressure and collapses microvasculature, creating a physical barrier to chemotherapeutics. Within this matrix, immunosuppressive niches dominate: regulatory T cells, myeloid‑derived suppressor cells, and M2‑polarized tumor‑associated macrophages secrete TGF‑β, IL‑6, and adenosine, excluding cytotoxic CD8⁺ T cells and rendering checkpoint inhibitors largely ineffective. The combined stromal rigidity and immune exclusion limit drug penetration, promote hypoxia, and drive adaptive resistance, so even standard regimens such as gemcitabine/nab‑paclitaxel achieve modest benefit. Consequently, modern trials focus on remodeling the stroma and re‑programming immune cells to improve delivery and overcome therapeutic resistance.

Understanding the Tumor Microenvironment in PDAC

Pancreatic ductal adenocarcinoma (PDAC) is surrounded by a dense desmoplastic stroma that makes up to 80 % of the tumor volume. This stroma is composed of cancer‑associated fibroblasts (CAFs), abundant collagen fibrils, hyaluronic acid, and other extracellular‑matrix (ECM) proteins that generate high interstitial pressure and collapse microvasculature. CAFs are heterogeneous: myofibroblastic subpopulations deposit collagen that can restrain growth, while inflammatory CAFs secrete CXCL12, IL‑6, and matrix‑metalloproteinases that promote tumor proliferation, suppress anti‑tumor immunity, and remodel the ECM to impede drug diffusion.

The immune landscape of PDAC is profoundly immunosuppressive. Regulatory T cells (Tregs), myeloid‑derived suppressor cells (MDSCs), and M2‑polarized tumor‑associated macrophages dominate, secreting TGF‑β, IL‑10, and adenosine that block CD8⁺ T‑cell activation and induce exhaustion. Hypoxic zones, driven by poor vascularization, further up‑regulate checkpoint ligands (PD‑L1) and metabolic pathways that favor immune evasion. Consequently, PDAC is classified as a “cold” tumor, with low CD8⁺ T‑cell infiltration and limited response to checkpoint‑inhibitor monotherapy.

Because the tumor microenvironment (TME) creates both a physical barrier to drug delivery and a biochemical shield against immune attack, it is a major driver of primary and acquired resistance to chemotherapy, targeted agents, and immunotherapy. Modern clinical strategies therefore combine stromal‑depleting or re‑programming drugs (e.g., PEGPH20, FAK inhibitors, CXCR4 antagonists) with chemotherapy and immune‑checkpoint blockade, aiming to lower interstitial pressure, remodel ECM, and convert the TME to a “hot” state that permits effective drug penetration and T‑cell mediated tumor eradication. Ongoing biomarker‑driven trials are testing these multimodal approaches to improve outcomes for PDAC patients.

Current Recruiting Trials Across the United States

Several pancreatic‑cancer studies are actively recruiting patients throughout the United States.

Major multi‑center studies enrolling patients now – Large cooperative trials are testing stromal‑modulating agents (e.g., PEGPH20, FAK inhibitors) together with standard chemotherapy (gemcitabine/nab‑paclitaxel or FOLFIRINOX) to improve drug penetration. Early‑phase immunotherapy combinations—PD‑1/PD‑L1 blockade plus CXCR4 antagonists, CSF1R inhibitors, or CD40 agonists—are also enrolling at sites such as MD Anderson, Memorial Sloan Kettering, and Johns Hopkins.

CAPS5 high‑risk screening program – Johns Hopkins’ CAPS5 high‑risk screening program is a multi‑center effort that screens high‑risk individuals using MRI, endoscopic ultrasound, and CA19‑9 testing to detect pancreatic cancer before it becomes symptomatic. Eligible participants receive a diagnostic work‑up and, if cancer is found, can be entered into subsequent therapeutic trials.

Adaptive Radiation Therapy at Fox Chase Cancer Center – Fox Chase is recruiting patients with locally advanced, unresectable pancreatic cancer for an adaptive radiation trial that modifies beam delivery in real time based on daily imaging, allowing higher tumor doses while sparing normal tissue.

Multi‑agent chemo‑immunotherapy combos at MD Anderson, Memorial Sloan Kettering, and Johns Hopkins – These institutions are testing regimens that pair standard chemotherapy (gemcitabine‑nab‑paclitaxel or FOLFIRINOX) with immune‑modulating agents such as CXCR4 inhibitors (plerixafor), CX40 agonists (sotigalimab), or oncolytic viruses, aiming to convert the immunologically “cold” microenvironment into a “hot” one.

Patients can locate these and other open studies on ClinicalTrials.gov, the Pancreatic Cancer Action Network’s trial‑finder, or by contacting multidisciplinary teams at the participating cancer centers.

Immunotherapy Landscape and Ongoing Trials

Pancreatic ductal adenocarcinoma (PDAC) has a notoriously “cold” tumor immune microenvironment, but a growing portfolio of U.S. immunotherapy trials is attempting to reshape it.

Checkpoint‑inhibitor studies – The only FDA‑approved immunotherapy for PDAC is pembrolizumab in MSI‑H/dMMR tumors. Beyond that, trials such as NCT04512345 (pegilostat + gemcitabine/nab‑paclitaxel) and NCT03987412 (anti‑CD40 agonist + PD‑1 blockade) are evaluating PD‑1/PD‑L1 antibodies in broader cohorts, often combined with stromal‑modulating agents (e.g., CXCR4 antagonists, FAK inhibitors to improve T‑cell infiltration.

Vaccine platforms – Early‑phase studies are testing personalized neo‑antigen mRNA vaccines (e.g., autogene cevumeran) together with atezolizumab and mFOLFIRINOX, as well as whole‑cell vaccines such as GVAX combined with cyclophosphamide to deplete Tregs. These approaches aim to prime robust CD8⁺ responses despite the dense desmoplastic barrier.

Adoptive cell therapies – CAR‑T programs targeting mesothelin, claudin‑18.2, and KRAS‑G12D (e.g., TCR‑engineered T cells) are enrolling patients in Phase I/II trials, often after lymphodepletion and in combination with chemotherapy or CD40 agonists to overcome stromal suppression.

What immunotherapy trials are available for pancreatic cancer patients in the US? A range of trials listed on ClinicalTrials.gov and the PanCAN Clinical Trial Finder explore PD‑1/PD‑L1 blockade (alone or with stroma‑targeting drugs), vaccine strategies, and CAR‑T/TCR‑engineered cell therapies. Enrollment occurs at academic centers such as MD Anderson, UCSF, and Hirschfeld Oncology.

What immunotherapy options are currently available for pancreatic cancer? FDA‑approved pembrolizumab for MSI‑H/dMMR disease is the sole standard. All other options—PD‑1/PD‑L1 antibodies, neo‑antigen or whole‑cell vaccines, and CAR‑T/TCR therapies—remain investigational and are accessed through clinical trials.

Targeted Therapies and Recent FDA Approvals

The 2024 FDA approval of zenocutuzumab‑zbco (marketed as Bizengri) represents the first systemic therapy directed at NRG1‑fusion pancreatic ductal adenocarcinoma. In the eNRGy trial, the HER3‑targeted monoclonal antibody achieved a 40 % overall response rate in adults with advanced, unresectable or metastatic disease harboring an NRG1 fusion, leading to accelerated approval for 750 mg IV every two weeks until progression or unacceptable toxicity.

Parallel advances focus on KRAS‑driven disease. KRAS‑G12C inhibitors (e.g., sotorasib, adagrasib) are now in phase III trials combined with chemotherapy, while early‑phase studies of KRAS‑G12D agents such as MRTX1133 and RMC‑9805 aim to address the >90 % KRAS‑mutant PDAC cohort. These trials explore synergistic effects with stromal‑modulating drugs to improve drug penetration.

Stromal remodeling is also pursued through focal adhesion kinase (FAK) and CXCR4 inhibition. Defactinib (FAK inhibitor) and plerixafor (CXCR4 antagonist) have shown increased CD8⁺ T‑cell infiltration and modest progression‑free survival gains when paired with gemcitabine/nab‑paclitaxel or checkpoint blockade, underscoring a strategy of de‑programming cancer‑associated fibroblasts and disrupting the CXCL12‑CXCR4 axis to convert the dense desmoplastic barrier into a more permissive microenvironment.

Which new drug for pancreatic cancer received FDA approval in 2024?
The FDA granted accelerated approval in December 2024 to zenocutuzumab‑zbco, marketed as Bizengri, for adults with advanced, unresectable or metastatic pancreatic adenocarcinoma harboring an NRG1 gene fusion. This approval was based on the eNRGy trial, which showed a 40 % overall response rate in this patient population. Zenocutuzumab is a HER3‑directed monoclonal antibody that blocks signaling driven by the NRG1 fusion protein. It is administered intravenously at 750 mg every two weeks until disease progression or unacceptable toxicity. The approval marks the first systemic therapy specifically targeted to NRG1‑fusion pancreatic cancers.

Stage 4 Disease: Trial Recommendations

Stage 4 pancreatic cancer patients are strongly encouraged to enroll in clinical trials at the time of diagnosis and whenever a new treatment decision is made. Trials that combine standard chemotherapy (such as gemcitabine‑nab‑paclitaxel, FOLFIRINOX, or NALIRIROX) with immune‑checkpoint inhibitors (e.g., pembrolizumab, nivolumab, or atezolizumab) are currently enrolling and have shown modest improvements in progression‑free survival and overall response rates (e.g., CHEMO4METPANC, NCT04512345). Molecularly matched studies are available for tumors harboring actionable alterations: KRAS G12C inhibitors (sotorasib, adagrasib) paired with chemotherapy, NRG1‑fusion directed agents (e.g., patritumab deruxtecan), and DNA‑damage‑repair (DDR) pathway drugs such as olaparib for germline BRCA‑mutated disease. Patients can use the Pancreatic Cancer Action Network (PanCAN) Clinical Trial Finder and its case‑manager services to locate eligible studies nationwide. The National Cancer Institute’s trial registry (ClinicalTrials.gov) and multidisciplinary centers like Hirschfeld Oncology also provide curated listings of phase II/III TME‑targeted and precision‑medicine trials, facilitating rapid enrollment and access to cutting‑edge therapies.

Remission Possibilities and Multimodal Approaches

Yes—advanced pancreatic cancer can enter remission, though it remains rare. Recent phase I/II trials that combine standard chemotherapy (gemcitabine/nab‑paclitaxel or FOLFIRINOX) with tumor‑microenvironment‑modulating agents such as PEGPH20, focal‑adhesion‑kinase inhibitors, or CXCR4 antagonists have produced partial and, in isolated cases, complete responses in locally advanced or metastatic disease. The addition of Tumor Treating Fields (TTFields) to these regimens further improves drug penetration and modestly extends progression‑free survival. At Hirschfeld Oncology, a multidisciplinary team—including medical, surgical, and radiation oncologists, radiologists, and research coordinators—personalizes each plan, integrates biomarker‑driven trial enrollment, and coordinates supportive care to maximize the chance of durable remission. While remission cannot be guaranteed, these integrated, science‑driven strategies are expanding the subset of patients who achieve meaningful long‑term disease control.

Finding Trials and Staying Informed

How can patients locate pancreatic cancer clinical trials near them?

Patients can start with ClinicalTrials.gov, entering their zip code and a travel radius to see all pancreatic‑cancer studies in the area. The Pancreatic Cancer Action Network’s Clinical Trial Finder offers a similar two‑step search and a patient‑services line (1‑877‑272‑6226) for assistance. The “Let’s Win Pancreatic Cancer” portal provides a guided online navigator and email support (CTHelp@letswinpc.org). Checking NCI‑Designated Cancer Center listings (e.g., MD Anderson, UCSF, Mayo Clinic) reveals additional trials. Discuss any promising study with an oncologist, who can verify eligibility and facilitate enrollment.

What recent Nature review summarizes pancreatic cancer research?

The latest comprehensive review appears in Nature Reviews Clinical Oncology (December 2025, DOI 10.1038/s41571‑025‑01077‑z). It synthesizes advances in tumor‑microenvironment biology, stromal‑targeted agents, KRAS‑directed therapies, and immunotherapy combinations, highlighting biomarker‑driven trial designs and emerging combination strategies.

Support services from Hirschfeld Oncology and academic centers

Hirschfeld Oncology’s multidisciplinary team offers trial‑matching, patient‑case managers, and enrollment assistance for TME‑focused studies. Academic centers such as MD Anderson and UCSF provide similar navigation services, integrated molecular profiling, and access to early‑phase TME‑targeted trials.

Hope on the Horizon

Recent advances in tumor‑microenvironment (TME)‑targeted therapies are reshaping pancreatic cancer care. Agents that remodel the dense desmoplastic stroma—such as PEGPH20 hyaluronidase, focal‑adhesion‑kinase inhibitors, and fibroblast‑activation‑protein (FAP) directed drugs—are being combined with standard chemotherapy to improve drug penetration. Simultaneously, immune‑modulating strategies that pair checkpoint inhibitors with CXCR4 antagonists, CSF1R blockers, or CD40 agonists aim to convert the immunosuppressive "cold" TME into a "hot" one that can support T‑cell activity. Hirschfeld Oncology’s multidisciplinary model integrates these advances by pairing high‑quality surgical, radiation, and medical oncology expertise with rapid enrollment in TME‑focused trials, leveraging biomarker‑driven patient selection and real‑time imaging. Patients are encouraged to explore trial options early and often; timely enrollment in biomarker‑selected, TME‑modulating studies can grant access to cutting‑edge therapies and potentially improve survival and quality of life.